Headlines

MID WEB AD_Vertical left side 426 pixels (height) x 170 pixels (width).gif

Lower cancer risk after MBS regardless of age or sex

Metabolic and bariatric surgery (MBS) reduces the risk of obesity-related cancer regardless of sex and age, according to a large Nordic registry study led by researchers at Karolinska Institutet. The results strengthen knowledge about the cancer-preventive effects of MBS for several cancers linked to obesity. "We found that the reduction in cancer risk after obesity surgery was similar across age groups and between women and men, suggesting that the long-term health benefits

Lower cancer risk after MBS regardless of age or sex

WHO does not recommend pharmacological treatment, bariatric surgery or weight-loss devices for children

Extreme obesity common among bariatric surgery patients should not preclude treatment

Research

Vogenx initiates EMERGE study of Mizagliflozin for post-bariatric hypoglycaemia

Vogenx has initiated the EMERGE (VGX-001-013) study - its Phase 2b clinical trial evaluating mizagliflozin for the treatment of post-bariatric hypoglycaemia (PBH). There are currently no therapeutics approved by the FDA for the treatment of PBH. EMERGE is a randomised, placebo-controlled, double-blind, parallel-group Phase 2b study designed to enrol approximately 36 adults who underwent bariatric surgery more than 12 months prior and who experience recurrent reactive hypoglyc

Lower cancer risk after MBS regardless of age or sex

General dietary interventions may matter more than specific habits before MBS

People preparing for metabolic and bariatric surgery (MBS) may eat quite differently from one another, but those differences do not necessarily translate into different measures of cardiometabolic health, according to a Concordia study. The researchers say the findings could help health professionals and patients inform lifestyle and eating habits in the lead-up to surgery, and earlier. Simon Bacon (Credit: Concordia University) Researchers identified two distinct dietary pro

Medtronic and Styker announce strategic investments in Cornerstone Robotics and CMR Surgical

Medtech giants, Medtronic and Stryker, have announced strategic investments in Cornerstone Robotics and CMR Surgical (CMR), respectively, as the companies seek to consolidate their positions in the robotic surgery market. Cornerstone Robotics' Sentire surgical system In early September, Medtronic revealed they had signed a strategic partnership with Cornerstone Robotics, in which Medtronic made an approximately $700 million investment includes rights to distribute Cornerstone

WHO does not recommend pharmacological treatment, bariatric surgery or weight-loss devices for children

The World Health Organization (WHO) has released its first guidelines addressing the sharp rise in obesity among children and adolescents, setting out how health systems and health workers can deliver timely, evidence-based and people-centred care. In the guidelines, WHO does not recommend pharmacological treatment, bariatric surgery or weight-loss devices for children aged 0–9 years. In 2024, 170 million children and adolescents aged 5–19 years were living with obesity, incl

Improve the evidence based across the board for GLP-1 RA use in women

The second of a series of papers presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2), presenters discussed the wide-ranging issues relating to use of GLP-1 RA drug use in women. The paper’s authors, including Professor Paul Franks, Lund University, Helsingborg Hospital, Helsingborg, Sweden and Professor Claire Meek, Leicester Diabetes Research Centre and Leicester NIHR Biomedical Research Centre, Leice

No link between semaglutide and pancreatic cancer

There is no link between semaglutide (a glucagon-like peptide-1 receptor agonist, GLP-1RA) use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway, according to at the Annual Meeting of The European Association for the Study of Diabetes (EASD). This regulator-mandated post authorisation study, funded by Novo Nordisk, was presented by Professor Anton Pottegård, University of Southern Denmark, Odense, Denmark, and colleagues. “This comprehensive

Michel Gagner - Master Surgeon Educator and innovator

In a career spanning decades, Professor Michel Gagner (Professor of Surgery in Montreal, Canada) has consistently pushed the boundaries of minimally invasive surgery. His lifelong dedication to surgical education was recently celebrated in Chicago, where he was inducted into the prestigious American College of Surgeons (ACS) Academy of Master Surgeon Educators. Michel Gagner Founded by Dr Ajit Sachdeva, this highly selective academy includes fewer than 250 surgeons out of 100

FDA approves Medtronic’s LigaSure RAS Maryland jaw device for use with the Hugo RAS system

The FDA has cleared Medtronic’s LigaSure robotic-assisted surgery (RAS) Maryland jaw device for use with the Hugo RAS system. The clearance expands the instruments available on the Hugo RAS system and brings Medtronic's trusted vessel-sealing technology to US surgeons performing robotic-assisted procedures. LigaSure robotic-assisted surgery Maryland jaw device As robotic-assisted surgery adoption grows in the US, surgeons increasingly expect the same trusted energy instrument

Bariatric medical tourism shifts as non-surgical options influence demand and post-op care

PlacidWay, a global medical tourism platform, has released industry research examining how the rapid adoption of non-surgical medications is influencing international healthcare travel patterns, including changing demand for bariatric surgery and increased interest in post-bariatric aesthetic care. The analysis identifies a shift in the traditional medical tourism pathway, particularly in medical tourism for bariatric surgery, as some patients who previously considered travel

Syntis Bio oral SYNT-101 demonstrates weight-loss and satiety hormone modulation

Results from Syntis Bio’s 28-day multiple ascending dose (MAD) portion of its Phase 1/1b SYNTIETY-1 clinical trial, evaluating SYNT-101 as a potential treatment of obesity, revealed that SYNT-101 was well tolerated at all dose levels in the MAD cohorts (n=23), with no discontinuations and no dose reductions in any of the cohorts. SYNT-101 is being developed as a once-daily pill for the treatment of obesity. SYNT-101 works by transiently blocking nutrient absorption in the pro

Dr Jaime Ponce assumes Presidency of IFSO

Dr Jaime Ponce has officially assumed the presidency of the International Federation for the Surgery and Other Therapies for Obesity (IFSO) during the closing ceremony of the XXIX IFSO World Congress in Toronto. Ponce received the leadership of the Federation from outgoing President, Dr Khaled Gawdat of Egypt, whom he recognised for his dedicated service and important contributions to IFSO and the global obesity-care community. "It is a tremendous honour to serve as President

Industry

Medtronic and Styker announce strategic investments in Cornerstone Robotics and CMR Surgical

Medtronic unveils Touch Surgery Aide - the next-generation compute platform for the OR

Shimadzu Medical Systems launches release of the FLUOROspeed X1 edition ST

First commercial EndoZip ESG cases performed in France

All caught up?

See all news

New: Directory

Discover global suppliers of specialist bariatric services, treatments, products, and medical equipment.

Browse directory

Events

Headlines

Lower cancer risk after MBS regardless of age or sex

Lower cancer risk after MBS regardless of age or sex

Lower cancer risk after MBS regardless of age or sex

WHO does not recommend pharmacological treatment, bariatric surgery or weight-loss devices for children

Extreme obesity common among bariatric surgery patients should not preclude treatment

Research

Vogenx initiates EMERGE study of Mizagliflozin for post-bariatric hypoglycaemia

Lower cancer risk after MBS regardless of age or sex

General dietary interventions may matter more than specific habits before MBS

Medtronic and Styker announce strategic investments in Cornerstone Robotics and CMR Surgical

WHO does not recommend pharmacological treatment, bariatric surgery or weight-loss devices for children

Improve the evidence based across the board for GLP-1 RA use in women

No link between semaglutide and pancreatic cancer

Michel Gagner - Master Surgeon Educator and innovator

FDA approves Medtronic’s LigaSure RAS Maryland jaw device for use with the Hugo RAS system

Bariatric medical tourism shifts as non-surgical options influence demand and post-op care

Syntis Bio oral SYNT-101 demonstrates weight-loss and satiety hormone modulation

Dr Jaime Ponce assumes Presidency of IFSO

Industry

Medtronic and Styker announce strategic investments in Cornerstone Robotics and CMR Surgical

Medtronic unveils Touch Surgery Aide - the next-generation compute platform for the OR

Shimadzu Medical Systems launches release of the FLUOROspeed X1 edition ST

First commercial EndoZip ESG cases performed in France

All caught up?

New: Directory

Discover global suppliers of specialist bariatric services, treatments, products, and medical equipment.

Events

(See all)

ALRSGBI Annunal Meeting 2026

6th LIBSS

Obesity Days

4th IFSO MENAC Meeting

London International Robotic Surgery Conference

6th London International Bariatric Surgery Symposium (LIBSS)

Tweets

Back to Top